Your Trusted Brand for Over 35 Years

Cancer Radiation Therapy References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Tobias JS. Clinical practice of radiotherapy. Lancet. 1992;339(8786):159-63.
  2. Burnet NG, Wurm R, et al. Normal tissue radiosensitivity--how important is it? Clin Oncol (R Coll Radiol). 1996;8(1):25-34.
  3. Emami B, Lyman J, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-22.
  4. Hoskin PJ, Price P, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992;23(2):74-8.
  5. Dunne-Daly CF. Principles of radiotherapy and radiobiology. Semin Oncol Nurs. 1999;15(4):250-9.
  6. Fang YZ, Yang S, et al. Free radicals, antioxidants, and nutrition. Nutrition. 2002;18(10):872-9.
  7. Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer. 1999;6(1):41-4.
  8. Kerr JF, Winterford CM, et al. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73(8):2013-26.
  9. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol. 2000;32(2):157-70.
  10. Shah N, Saunders MI, et al. A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. Clin Oncol (R Coll Radiol). 2000;12(6):392-6.
  11. Fu KK, Pajak TF, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7-16.
  12. Goodchild K, Hoskin P, et al. A feasibility study of continuous hyperfractionated accelerated radiotherapy (CHART) and brachytherapy in patients with early oral or oropharyngeal carcinomas. Radiother Oncol. 1999 Jan;50(1):29-31.
  13. Ghosh S, Sujendran V, et al. Long term results of surgery versus continuous hyperfractionated accelerated radiotherapy (CHART) in patients aged >70 years with stage 1 non-small cell lung cancer. Eur J Cardiothorac Surg. 2003 Dec;24(6):1002-7.
  14. Suit HD. Protons to replace photons in external beam radiation therapy? Clin Oncol (R Coll Radiol ). 2003 Feb;15(1):S29-S31.
  15. Shipley WU, Verhey LJ, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):3-12.
  16. Slater JD, Rossi CJ, Jr, et al. Conformal proton therapy for early-stage prostate cancer. Urology. 1999 May;53(5):978-84.
  17. Zietman AL, DeSilvio ML, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9.
  18. Bush DA, Slater JD, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999 Nov;116(5):1313-9.
  19. Matsuzaki Y, Osuga T, et al. New, effective treatment using proton irradiation for unresectable hepatocellular carcinoma. Intern Med. 1995 Apr;34(4):302-4.
  20. Courdi A, Caujolle JP, et al. Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):5-11.
  21. Munzenrider JE. Proton therapy for uveal melanomas and other eye lesions. Strahlenther Onkol. 1999a Jun;175 Suppl 2:68-73.
  22. Spatola C, Privitera G, et al. Clinical application of proton beams in the treatment of uveal melanoma: the first therapies carried out in Italy and preliminary results (CATANA Project). Tumori. 2003 Sep;89(5):502-9.
  23. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999b Jun;175 Suppl 2:57-63.
  24. Fuss M, Hug EB, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1117-26.
  25. Habrand JL, Haie-Meder C, et al. [Radiotherapy using a combination of photons and protons for locally aggressive intracranial tumors. Preliminary results of protocol CPO 94-C1]. Cancer Radiother. 1999 Nov;3(6):480-8.
  26. Gudjonsson O, Blomquist E, et al. Stereotactic irradiation of skull base meningiomas with high energy protons. Acta Neurochir (Wien ). 1999;141(9):933-40.
  27. Koyama S, Tsujii H. Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3571-7.
  28. Ask A, Johansson B, et al. The potential of proton beam radiation therapy in gastrointestinal cancer. Acta Oncol. 2005b;44(8):896-903.
  29. Ask A, Bjork-Eriksson T, et al. The potential of proton beam radiation therapy in head and neck cancer. Acta Oncol. 2005a;44(8):876-80.
  30. Sugahara S, Tokuuye K, et al. Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):76-84.
  31. Hurkmans CW, Cho BC, et al. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol. 2002;62(2):163-71.
  32. Nutting C, Dearnaley DP, et al. Intensity modulated radiation therapy: a clinical review. Br J Radiol. 2000;73(869):459-69.
  33. Garden AS, Morrison WH, et al. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol. 2004;14(2):103-9.
  34. Welsh JS, Limmer JP, et al. Precautions in the use of intensity-modulated radiation therapy. Technol Cancer Res Treat. 2005;4(2):203-10.
  35. De Meerleer G, Vakaet L, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys. 2004;60(3):777-87.
  36. Ahmed RS, Kim RY, et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys. 2004;60(2):505-12.
  37. Kwong DL, Pow EH, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer. 2004;101(7):1584-93.
  38. Penagaricano JA, Papanikolaou N, et al. Application of intensity-modulated radiation therapy for pediatric malignancies. Med Dosim. 2004;29(4):247-53.
  39. Woolsey J, Miller N, et al. Permanent interstitial brachytherapy for prostate cancer: a current review. World J Urol. 2003;21(4):209-19.
  40. Nakano T, Kato S, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer. 2005;103(1):92-101.
  41. Fieler VK. Side effects and quality of life in patients receiving high-dose rate brachytherapy. Oncol Nurs Forum. 1997;24(3):545-53.
  42. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5(5):292-302.
  43. Witzig TE, Gordon LI, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(10):2453-63.
  44. Riley MB, Byar K. The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphoma. Semin Oncol Nurs. 2004;20(1 Suppl 1):1-7.
  45. Witzig TE, White CA, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol. 2003;21(7):1263-70.
  46. Phillips MH, Stelzer KJ, et al. Stereotactic radiosurgery: a review and comparison of methods. J Clin Oncol. 1994;12(5):1085-99.
  47. Song DY, Kavanagh BD, et al. Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology (Huntingt). 2004;18(11):1419-30.
  48. Gerszten PC, Welch WC. Cyberknife radiosurgery for metastatic spine tumors. Neurosurg Clin N Am. 2004b Oct;15(4):491-501.
  49. Gerszten PC, Ozhasoglu C, et al. CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery. 2004a Jul;55(1):89-98.
  50. Bhatnagar AK, Gerszten PC, et al. CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors. Technol Cancer Res Treat. 2005 Oct;4(5):571-6.
  51. Degen JW, Gagnon GJ, et al. CyberKnife stereotactic radiosurgical treatment of spinal tumors for pain control and quality of life. J Neurosurg Spine. 2005 May;2(5):540-9.
  52. Symonds RP. Recent advances: Radiotherapy. Bmj. 2001;323(7321):1107-10.
  53. Perez CA, Michalski JM, et al. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update. Clin Prostate Cancer. 2002;1(2):97-104.
  54. Ron E. Cancer risks from medical radiation. Health Phys. 2003;85(1):47-59.
  55. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet. 2004;363(9406):345-51.
  56. McCreath GT, O'Neill KF, et al. Audit of chest X-rays in general practice--a case for local guidelines? Health Bull (Edinb). 1999;57(3):180-5.
  57. Fleszler F, Friedenberg F, et al. Abdominal computed tomography prolongs length of stay and is frequently unnecessary in the evaluation of acute pancreatitis. Am J Med Sci. 2003;325(5):251-5.
  58. Frush DP. Review of radiation issues for computed tomography. Semin Ultrasound CT MR. 2004;25(1):17-24.
  59. Brenner D, Elliston C, et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001;176(2):289-96.
  60. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001a;358(9290):1340-2.
  61. Sabel M, Aichinger U, et al. [Radiation exposure in x-ray mammography]. Rofo. 2001;173(2):79-91.
  62. Beckett JR, Kotre CJ, et al. Analysis of benefit:risk ratio and mortality reduction for the UK Breast Screening Programme. Br J Radiol. 2003;76(905):309-20.
  63. Brenner DJ, Sawant SG, et al. Routine screening mammography: how important is the radiation-risk side of the benefit-risk equation? Int J Radiat Biol. 2002;78(12):1065-7.
  64. Wakeford R. The cancer epidemiology of radiation. Oncogene. 2004;23(38):6404-28.
  65. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56(1):83-8.
  66. Porock D. Factors influencing the severity of radiation skin and oral mucosal reactions: development of a conceptual framework. Eur J Cancer Care (Engl). 2002;11(1):33-43.
  67. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev. 2004;23(3-4):237-57.
  68. Alsner J, Sorensen SB, et al. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol. 2001;59(2):179-85.
  69. Ma L, Ronai A, et al. Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol. 1998;124(7):389-96.
  70. Saunders M, Dische S, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999;52(2):137-48.
  71. Li R, Heydon K, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 2004;10(12 Pt 1):4118-24.
  72. Wilson GD, Saunders MI, et al. Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human tumours. Cell Prolif. 1996;29(3):141-52.
  73. Knight K, Wade S, et al. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116 Suppl 7A:11S-26S.
  74. Henke M, Sindlinger F, et al. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol. 2004;180(1):45-51.
  75. Winter WE 3rd, Maxwell GL, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 2004;94(2):495-501.
  76. Daly T, Poulsen MG, et al. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2003;68(2):113-22.
  77. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol. 2001;28(2 Suppl 8):7-14.
  78. Dunst J. Management of Anemia in Patients Undergoing Curative RadiotherapyErythropoietin, Transfusions, or Better Nothing? Strahlenther Onkol. 2004;180(11):671-81.
  79. Tarnawski R, Skladowski K, et al. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys. 1997;38(5):1007-11.
  80. Grogan M, Thomas GM, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86(8):1528-36.
  81. Olijhoek G, Megens JG, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion. 2001;41(7):957-63.
  82. Bokemeyer C, Aapro MS, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40(15):2201-16.
  83. Cheer SM, Wagstaff AJ. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs. 2004;64(3):323-46.
  84. Stuben G, Pottgen C, et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys. 2003;55(5):1358-62.
  85. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004;9 Suppl 5:31-40.
  86. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14(3):198-206.
  87. Brizel DM, Scully SP, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56(5):941-3.
  88. Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol. 2004;43(4):396-403.
  89. Fridovich I. Fundamental aspects of reactive oxygen species, or what's the matter with oxygen? Ann N Y Acad Sci. 1999;893:13-8.
  90. Coleman CN. Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!). Radiology. 2003;228(1):29-35.
  91. Vaupel P, Thews O, et al. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2001;18(4):243-59.
  92. Overgaard J, Eriksen JG, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6(10):757-64.
  93. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today. 2000;6(4):157-62.
  94. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004b;4(6):437-47.
  95. Brown JM. Hypoxic cell radiosensitizers: the end of an era? Regarding Lee et al., IJROBP 32:567-576; 1995. Int J Radiat Oncol Biol Phys. 1995;32(3):883-5.
  96. Kaanders JH, Bussink J, et al. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol. 2004;14(3):233-40.
  97. Shweiki D, Itin A, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843-5.
  98. Tozer GM, Bicknell R. Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol. 2004;14(3):222-32.
  99. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10(2):415-27.
  100. Yang SH, Lin JK, et al. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res. 2003 Jul;113(1):133-8.
  101. Gururaj AE, Belakavadi M, et al. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun. 2002 Oct 4;297(4):934-42.
  102. Feldmeier JJ. Hyperbaric oxygen for delayed radiation injuries. Undersea Hyperb Med. 2004;31(1):133-45.
  103. Plafki C, Carl UM, et al. The treatment of late radiation effects with hyperbaric oxygenation (HBO). Strahlenther Onkol. 1998;174 Suppl 3:66-8.
  104. Anderson DW. Using hyperbaric oxygen therapy to heal radiation wounds. Nursing. 2003;33(9):50-3.
  105. Marx RE, Ehler WJ, et al. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg. 1990 Nov;160(5):519-24.
  106. Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med. 2002;29(1):4-30.
  107. Corman JM, McClure D, et al. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. J Urol. 2003;169(6):2200-2.
  108. Carl W, Emrich LS. Management of oral mucositis during local radiation and systemic chemotherapy: a study of 98 patients. J Prosthet Dent. 1991;66(3):361-9.
  109. Mayer R, Klemen H, et al. Hyperbaric oxygen--an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol. 2001;61(2):151-6.
  110. Kohshi K, Imada H, et al. Successful treatment of radiation-induced brain necrosis by hyperbaric oxygen therapy. J Neurol Sci. 2003 May 15;209(1-2):115-7.
  111. Bui QC, Lieber M, et al. The efficacy of hyperbaric oxygen therapy in the treatment of radiation-induced late side effects. Int J Radiat Oncol Biol Phys. 2004;60(3):871-8.
  112. Mounsey RA, Brown DH, et al. Role of hyperbaric oxygen therapy in the management of mandibular osteoradionecrosis. Laryngoscope. 1993 Jun;103(6):605-8.
  113. Reuther T, Schuster T, et al. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients--a report of a thirty year retrospective review. Int J Oral Maxillofac Surg. 2003 Jun;32(3):289-95.
  114. Gothard L, Stanton A, et al. Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. Radiother Oncol. 2004 Mar;70(3):217-24.
  115. Haffty BG, Hurley R, et al. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial. Cancer J Sci Am. 1999 Nov;5(6):341-7.
  116. Sundfor K, Trope C, et al. Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix. Results from a prospective controlled randomized trial. Radiother Oncol. 1999 Feb;50(2):157-65.
  117. Zajusz A, Maciejewski B, et al. Normobaric oxygen as a sensitizer in radiotherapy for advanced head and neck cancer. Neoplasma. 1995;42(3):137-40.
  118. Yuhas JM, Yurconic M, et al. Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy. Radiat Res. 1977;70(2):433-43.
  119. Jackson D, Kinsella T, et al. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme. Am J Clin Oncol. 1987;10(5):437-43.
  120. Brown JM. Keynote address: hypoxic cell radiosensitizers: where next? Int J Radiat Oncol Biol Phys. 1989;16(4):987-93.
  121. Hensley ML, Schuchter LM, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17(10):3333-55.
  122. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol. 2000;72(4):425-35.
  123. Yun TK. Panax ginseng--a non-organ-specific cancer preventive? Lancet Oncol. 2001;2(1):49-55.
  124. Kim SR, Jo SK, et al. Modification of radiation response in mice by ginsenosides, active components of Panax ginseng. In Vivo. 2003;17(1):77-81.
  125. Kim TH, Lee YS, et al. Protective effect of ginseng on radiation-induced DNA double strand breaks and repair in murine lymphocytes. Cancer Biother Radiopharm. 1996;11(4):267-72.
  126. Lee TK, Allison RR, et al. Ginseng reduces the micronuclei yield in lymphocytes after irradiation. Mutat Res. 2004a;557(1):75-84.
  127. Xie FY, Huang HY, et al. Observation on effect of radiotherapy and antike capsule combination therapy in treating nasopharyngeal cancer patients. [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi. 2001;21(12):888-90.
  128. Walzem RL, Dillard CJ, et al. Whey components: millennia of evolution create functionalities for mammalian nutrition: what we know and what we may be overlooking. Crit Rev Food Sci Nutr. 2002;42(4):353-75.
  129. Kennedy RS, Konok GP, et al. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study. Anticancer Res. 1995;15(6B):2643-9.
  130. Todorova VK, Harms SA, et al. Effect of dietary glutamine on tumor glutathione levels and apoptosis-related proteins in DMBA-induced breast cancer of rats. Breast Cancer Res Treat. 2004;88(3):247-56.
  131. Klimberg VS, Nwokedi E, et al. Glutamine facilitates chemotherapy while reducing toxicity. JPEN J Parenter Enteral Nutr. 1992;16(6 Suppl):83S-7S.
  132. Rouse K, Nwokedi E, et al. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg. 1995;221(4):420-6.
  133. See D, Mason S, et al. Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol Invest. 2002;31(2):137-53.
  134. Wara WM, Wara DW, et al. Immunosuppression and reconstitution with thymosin after radiation therapy. Int J Radiat Oncol Biol Phys. 1979 Jul;5(7):997-1001.
  135. Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000;20(6C):4785-92.
  136. Marshall K. Therapeutic applications of whey protein. Altern Med Rev. 2004;9(2):136-56.
  137. Krotkiewski M, Przybyszewska M, et al. Cytostatic and cytotoxic effects of alkylglycerols (Ecomer). Med Sci Monit. 2003 Nov;9(11):I131-I135.
  138. Hasle H, Rose C. [Shark liver oil (alkoxyglycerol) and cancer treatment]. Ugeskr Laeger. 1991 Jan 28;153(5):343-6.
  139. Hichami A, Duroudier V, et al. Modulation of platelet-activating-factor production by incorporation of naturally occurring 1-O-alkylglycerols in phospholipids of human leukemic monocyte-like THP-1 cells. Eur J Biochem. 1997 Dec 1;250(2):242-8.
  140. Tchorzewski H, Banasik M, et al. [Modification of innate immunity in humans by active components of shark liver oil]. Pol Merkuriusz Lek. 2002 Oct;13(76):329-32.
  141. Pugliese PT, Jordan K, et al. Some biological actions of alkylglycerols from shark liver oil. J Altern Complement Med. 1998;4(1):87-99.
  142. van der Zee J. Heating the patient: a promising approach? Ann Oncol. 2002;13(8):1173-84.
  143. Song CW, Shakil A, et al. Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen. Semin Oncol. 1997;24(6):626-32.
  144. van der Zee J, Hulshof MC. Lessons learned from hyperthermia. Int J Radiat Oncol Biol Phys. 2003;57(2):596-7.
  145. Fajardo LF. Pathological effects of hyperthermia in normal tissues. Cancer Res. 1984;44(10 Suppl):4826s-35s.
  146. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett. 2004;215(2):129-40.
  147. Sarkar FH, Li Y. Cell signaling pathways altered by natural chemopreventive agents. Mutat Res. 2004;555(1-2):53-64.
  148. Katiyar SK, Afaq F, et al. Green tea polyphenol (-)-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress. Carcinogenesis. 2001;22(2):287-94.
  149. Lee YK, Bone ND, et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004b;104(3):788-94.
  150. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Exs. 2005;(94):209-31.
  151. Yashar CM, Spanos WJ, et al. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol Oncol. 2005 Oct;99(1):199-205.
  152. Kotowski U, Heiduschka G, Brunner M, et al. Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane. Strahlenther Onkol. 2011 Sep;187(9):575-80.
  153. Sikora E, Bielak-Zmijewska A, et al. Inhibition of proliferation and apoptosis of human and rat T lymphocytes by curcumin, a curry pigment. Biochem Pharmacol. 1997;54(8):899-907.
  154. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995;270(42):24995-5000.
  155. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002;64(5-6):883-8.
  156. Khafif A, Hurst R. et al. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg. 2005 Feb;132(2):317-21.
  157. Chendil D, Ranga RS, et al. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 2004 Feb 26;23(8):1599-607.
  158. Richardson MA, Sanders T, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18(13):2505-14.
  159. Salganik RI. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr. 2001;20(5 Suppl):464S-72S.
  160. Block KI. Antioxidants and cancer therapy: furthering the debate. Integr Cancer Ther. 2004;3(4):342-8.
  161. Schuchter LM, Hensley ML, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20(12):2895-903.
  162. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev. 1999;4(5):304-29.
  163. Sabitha KE, Shyamaladevi CS. Oxidant and antioxidant activity changes in patients with oral cancer and treated with radiotherapy. Oral Oncology. 1999;35(3):273-7.
  164. Prasad KN, Cole WC, et al. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev. 2002;28(2):79-91.
  165. Seifried HE, McDonald SS, et al. The antioxidant conundrum in cancer. Cancer Res. 2003;63(15):4295-8.
  166. Kiremidjian-Schumacher L, Roy M, et al. Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res. 2000;73(2):97-111.
  167. Malmberg KJ, Lenkei R, et al. A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res. 2002;8(6):1772-8.
  168. De Maria D, Falchi AM, et al. Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial in patients operated on for endometrial cancer. Tumori. 1992;78(6):374-6.
  169. Ersin S, Tuncyurek P, et al. The prophylactic and therapeutic effects of glutamine- and arginine-enriched diets on radiation-induced enteritis in rats. J Surg Res. 2000;89(2):121-5.
  170. Huang EY, Leung SW, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys. 2000;46(3):535-9.
  171. Kaya E, Gur ES, et al. L-glutamine enemas attenuate mucosal injury in experimental colitis. Dis Colon Rectum. 1999;42(9):1209-15.
  172. Kim JA, Baker DG, et al. Topical use of N-acetylcysteine for reduction of skin reaction to radiation therapy. Semin Oncol. 1983;10(1 Suppl 1):86-92.
  173. Klimberg VS, Salloum RM, et al. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch Surg. 1990;125(8):1040-5.
  174. Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. Br J Cancer. 1988;57(4):416-7.
  175. Wagdi P, Fluri M, et al. Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. A pilot study. Jpn Heart J. 1996;37(3):353-9.
  176. Foley DJ, White LR. Dietary intake of antioxidants and risk of Alzheimer disease: food for thought. Jama. 2002;287(24):3261-3.
  177. Shahidi F. Antioxidants in food and food antioxidants. Nahrung. 2000;44(3):158-63.
  178. Tannock IF, Suit HD, et al. Vitamin A and the radiation response of experimental tumors: an immune-mediated effect. J Natl Cancer Inst. 1972;48(3):731-41.
  179. Levitsky J, Hong JJ, et al. Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case. Dis Colon Rectum. 2003;46(5):679-82.
  180. Ehrenpreis ED, Jani A, et al. A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum. 2005;48(1):1-8.
  181. Beliaev IK. [Evaluation and correction of the vitamin C status in relation to the problem of the experimental modification of long-term radiation effects]. Radiobiologiia. 1991 Nov;31(6):819-23.
  182. Tewfik FA, Tewfik HH, et al. The influence of ascorbic acid on the growth of solid tumors in mice and on tumor control by X-irradiation. Int J Vitam Nutr Res Suppl. 1982;23:257-63.
  183. Kumar B, Jha MN, et al. D-alpha-tocopheryl succinate (vitamin E) enhances radiation-induced chromosomal damage levels in human cancer cells, but reduces it in normal cells. J Am Coll Nutr. 2002;21(4):339-43.
  184. Weiss JF, Landauer MR. Radioprotection by antioxidants. Ann N Y Acad Sci. 2000;899:44-60.
  185. Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology. 2003;189(1-2):1-20.
  186. Schueller P, Puettmann S, et al. Selenium influences the radiation sensitivity of C6 rat glioma cells. Anticancer Res. 2004;24(5A):2913-7.
  187. Lockwood K, Moesgaard S, et al. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med. 1994;15 Suppl:231-40.
  188. Lockwood K, Moesgaard S, et al. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun. 1995;212(1):172-7.
  189. Lund EL, Quistorff B, et al. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha). 1998;43(5):505-6.
  190. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res. 2004;37(3):213-4.
  191. Karbownik M, Reiter RJ. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proc Soc Exp Biol Med. 2000 Oct;225(1):9-22.
  192. Vijayalaxmi, Reiter RJ, et al. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys. 2004;59(3):639-53.
  193. Blask DE, Hill SM. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J Neural Transm Suppl. 1986;21:433-49.
  194. Subramanian A, Kothari L. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis. Anticancer Drugs. 1991;2(3):297-303.
  195. Conti A, Maestroni GJ. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res. 1995;19(3):103-10.
  196. Lissoni P, Meregalli S, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996a;53(1):43-6.
  197. Vijayalaxmi, Reiter RJ, Herman TS, et al. Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes. Mutat Res. 1998 Feb;397(2):203-8.
  198. Karslioglu I, Ertekin MV, et al. Radioprotective effects of melatonin on radiation-induced cataract. J Radiat Res (Tokyo). 2005 Jun;46(2):277-82.
  199. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23(2):457-67.
  200. Herskind C, Bamberg M, et al. The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol. 1998;174 Suppl 3:12-5.
  201. Lipshultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol. 1993;11(7):1199-203.
  202. Lee CK, Aeppli D, et al. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48(1):169-79.
  203. Gyenes G, Rutqvist LE, et al. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol. 1998;48(2):185-90.
  204. Resbeut M, Marteau P, et al. A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol. 1997;44(1):59-63.
  205. Ajlouni M. Radiation-induced Proctitis. Curr Treat Options Gastroenterol. 1999;2(1):20-6.
  206. Denton AS, Bond SJ, et al. National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. Clin Oncol (R Coll Radiol). 2000;12(6):347-53.
  207. Hall JC, Heel K, et al. Glutamine. Br J Surg. 1996;83(3):305-12.
  208. Gurbuz AT, Kunzelman J, et al. Supplemental dietary arginine accelerates intestinal mucosal regeneration and enhances bacterial clearance following radiation enteritis in rats. J Surg Res. 1998;74(2):149-54.
  209. Hwang JM, Chan DC, et al. Effects of oral arginine and glutamine on radiation-induced injury in the rat. J Surg Res. 2003;109(2):149-54.
  210. Kozelsky TF, Meyers GE, et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol. 2003;21(9):1669-74.
  211. Savarese DM, Savy G, et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003 Dec;29(6):501-13.
  212. Yoshida S, Matsui M, et al. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Ann Surg. 1998 Apr;227(4):485-91.
  213. Ennis RD. Hyperbaric oxygen for the treatment of radiation cystitis and proctitis. Curr Urol Rep. 2002;3(3):229-31.
  214. Chong KT, Hampson NB, et al. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology. 2005 Apr;65(4):649-53.
  215. Neheman A, Nativ O, et al. Hyperbaric oxygen therapy for radiation-induced haemorrhagic cystitis. BJU Int. 2005 Jul;96(1):107-9.
  216. Cook SI, Sellin JH. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther. 1998;12(6):499-507.
  217. Kim YI. Short-chain fatty acids in ulcerative colitis. Nutr Rev. 1998;56(1 Pt 1):17-24.
  218. al-Sabbagh R, Sinicrope FA, et al. Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol. 1996;91(9):1814-6.
  219. Vernia P, Fracasso PL, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet. 2000;356(9237):1232-5.
  220. Irvine L, Jodrell N. The distress associated with cranial irradiation: a comparison of patient and nurse perceptions. Cancer Nurs. 1999;22(2):126-33.
  221. Oxenkrug G, Requintina P, et al. Antioxidant and antiaging activity of N-acetylserotonin and melatonin in the in vivo models. Ann N Y Acad Sci. 2001;939:190-9.
  222. Fischer TW, Burmeister G, et al. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150(2):341-5.
  223. Cheng JC, Chuang VP, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2000;47(2):435-42.
  224. Cheng JC, Wu JK, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys. 2002b;54(1):156-62.
  225. Lawrence TS, Robertson JM, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237-48.
  226. Cheng JC, Wu JK, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol. 2002a;63(1):41-5.
  227. Levy C, Seeff LD, et al. Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol. 2004;2(11):947-56.
  228. Saller R, Meier R, et al. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63.
  229. Feher J, Lang I, et al. Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease. Free Radic Res Commun. 1987;3(6):373-7.
  230. Soto C, Recoba R, et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol. 2003;136(3):205-12.
  231. Ladas EJ, Kelly KM. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J Altern Complement Med. 2003;9(3):411-6.
  232. Ramadan LA, Roushdy HM, et al. Radioprotective effect of silymarin against radiation induced hepatotoxicity. Pharmacol Res. 2002;45(6):447-54.
  233. Lucena MI, Andrade RJ, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther. 2002 Jan;40(1):2-8.
  234. Velussi M, Cernigoi AM, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997 Apr;26(4):871-9.
  235. Fisher J, Scott C, et al. Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13. Int J Radiat Oncol Biol Phys. 2000;48(5):1307-10.
  236. Westbury C, Hines F, et al. Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial. Radiother Oncol. 2000;54(2):109-16.
  237. Wickline MM. Prevention and treatment of acute radiation dermatitis: a literature review. Oncol Nurs Forum. 2004;31(2):237-47.
  238. Margolin SG, Breneman JC, et al. Management of radiation-induced moist skin desquamation using hydrocolloid dressing. Cancer Nurs. 1990;13(2):71-80.
  239. Bostrom A, Lindman H, et al. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol. 2001;59(3):257-65.
  240. Schmuth M, Wimmer MA, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol. 2002;146(6):983-91.
  241. Fenig E, Brenner B, et al. Topical Biafine and Lipiderm for the prevention of radiation dermatitis: a randomized prospective trial. Oncol Rep. 2001;8(2):305-9.
  242. Pommier P, Gomez F, et al. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol. 2004;22(8):1447-53.
  243. Heggie S, Bryant GP, et al. A Phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue. Cancer Nurs. 2002;25(6):442-51.
  244. Williams MS, Burk M, et al. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys. 1996;36(2):345-9.
  245. Olsen DL, Raub W, Jr, et al. The effect of aloe vera gel/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy. Oncol Nurs Forum. 2001b;28(3):543-7.
  246. Roper B, Kaisig D, et al. Theta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care? Strahlenther Onkol. 2004;180(5):315-22.
  247. Lokkevik E, Skovlund E, et al. Skin treatment with bepanthen cream versus no cream during radiotherapy--a randomized controlled trial. Acta Oncol. 1996;35(8):1021-6.
  248. Baier JE, Neumann HA, et al. [Radiation protection through cytokine release by N-acetylcysteine]. Strahlenther Onkol. 1996 Feb;172(2):91-8.
  249. Horrobin DF. Nutritional and medical importance of gamma-linolenic acid. Prog Lipid Res. 1992;31(2):163-94.
  250. Hopewell JW, van den Aardweg GJ, et al. Amelioration of both early and late radiation-induced damage to pig skin by essential fatty acids. Int J Radiat Oncol Biol Phys. 1994;30(5):1119-25.
  251. Lee TK, Stupans I. Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins. J Pharm Pharmacol. 2002 Nov;54(11):1435-45.
  252. Burger A, Loffler H, et al. Molecular and cellular basis of radiation fibrosis. Int J Radiat Biol. 1998;73(4):401-8.
  253. Delanian S, Balla-Mekias S, et al. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol. 1999;17(10):3283-90.
  254. Futran ND, Trotti A, et al. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Laryngoscope. 1997 Mar;107(3):391-5.
  255. Rudolph R, Vande Berg J, et al. Slowed growth of cultured fibroblasts from human radiation wounds. Plast Reconstr Surg. 1988;82(4):669-77.
  256. Delanian S, Porcher R, et al. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol. 2003;21(13):2545-50.
  257. Allegra C, Sarcinella R, et al. Morphologic and functional changes of the microlymphatic network in patients with advancing stages of primary lymphedema. Lymphology. 2002;35(3):114-20.
  258. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998;83(12 Suppl American):2776-81.
  259. Dietz A, Rudat V, et al. [Chronic laryngeal edema as a late reaction to radiochemotherapy]. Hno. 1998;46(8):731-8.
  260. Harris SR, Hugi MR, et al. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. Cmaj. 2001;164(2):191-9.
  261. Collins CD, Mortimer PS, et al. Computed tomography in the assessment of response to limb compression in unilateral lymphoedema. Clin Radiol. 1995;50(8):541-4.
  262. Dini D, Del Mastro L, et al. The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. Ann Oncol. 1998;9(2):187-90.
  263. Granda C. Nursing management of patients with lymphedema associated with breast cancer therapy. Cancer Nurs. 1994;17(3):229-35.
  264. Johansson K, Ohlsson K, et al. Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study. Lymphology. 2002;35(2):59-71.
  265. Bruns F, Buntzel J, et al. Selenium in the treatment of head and neck lymphedema. Med Princ Pract. 2004;13(4):185-90.
  266. Kasseroller RG, Schrauzer GN. Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: a review. Am J Ther. 2000;7(4):273-9.
  267. Micke O, Bruns F, et al. Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys. 2003;56(1):40-9.
  268. Zimmermann T, Leonhardt H, et al. Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res. 2005 Sep;106(3):193-203.
  269. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003;23(5):486-99.
  270. Cohen EP, Piering WF, et al. End-stage renal disease (ESRD)after bone marrow transplantation: poor survival compar ed to other causes of ESRD. Nephron. 1998;79(4):408-12.
  271. Levey AS, Greene T, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999 Nov;10(11):2426-39.
  272. Youngman LD. Protein restriction (PR) and caloric restriction (CR) compared: effects on DNA damage, carcinogenesis, and oxidative damage. Mutat Res. 1993 Dec;295(4-6):165-79.
  273. Moulder JE, Fish BL, et al. Retinoic acid exacerbates experimental radiation nephropathy. Radiat Res. 2002;157(2):199-203.
  274. Liang BC. Radiation-Associated Neurotoxicity. Hospital Physician. 1999;54-8.
  275. Chong VF, Khoo JB, et al. Neurological changes following radiation therapy for head and neck tumours. Eur J Radiol. 2002;44(2):120-9.
  276. Young DF, Posner JB, et al. Rapid-course radiation therapy of cerebral metastases: results and complications. Cancer. 1974;34(4):1069-76.
  277. Keime-Guibert F, Napolitano M. et al. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245(11):695-708.
  278. Lyubimova N, Hopewell JW. Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation-induced CNS injury. Br J Radiol. 2004;77(918):488-92.
  279. Wen PY, Alexander E, et al. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994;73(12):3029-36.
  280. Strohl RA. Radiation therapy in tumors of the central nervous system. Semin Oncol Nurs. 1998;14(1):26-33.
  281. Chuba PJ, Aronin P, et al. Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer. 1997;80(10):2005-12.
  282. Hornsey S, Myers R, et al. The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs. Int J Radiat Oncol Biol Phys. 1990;18(6):1437-42.
  283. Dion MW, Hussey DH, et al. Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):401-7.
  284. Hart GB, Mainous EG. The treatment of radiation necrosis with hyperbaric oxygen (OHP). Cancer. 1976 Jun;37(6):2580-5.
  285. Ozturk B, Egehan I, et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):213-9.
  286. Aygenc E, Celikkanat S, et al. Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg. 2004 Mar;130(3):351-6.
  287. Hong JH, Chiang CS, et al. Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):619-26.
  288. Delanian S, Lefaix JL. Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate. Br J Radiol. 2002b May;75(893):467-9.
  289. Delanian S, Lefaix JL. [Reversibility of radiation-induced fibroatrophy]. Rev Med Interne. 2002a Feb;23(2):164-74.
  290. Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys. 2001;49(4):917-30.
  291. Sonis ST, Oster G, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201-5.
  292. Dodd MJ, Larson PJ, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum. 1996;23(6):921-7.
  293. Clarkson JE, Worthington HV, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2003;(3):CD000978.
  294. Worthington HV, Clarkson JE, et al. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2004;(2):CD001973.
  295. Shieh SH, Wang ST, et al. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncol. 1997;33(1):36-41.
  296. Dodd MJ, Dibble SL, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(1):39-47.
  297. Biswal BM, Zakaria A, et al. Topical application of honey in the management of radiation mucositis: a preliminary study. Support Care Cancer. 2003;11(4):242-8.
  298. Donnelly JP, Bellm LA, et al. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis. 2003;3(7):405-12.
  299. Okuno SH, Foote RL, et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer. 1997;79(11):2193-9.
  300. Spijkervet FK, Van Saene HK, et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol. 1991;46(3):167-73.
  301. Symonds RP, McIlroy P, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer. 1996;74(2):312-7.
  302. Stokman MA, Spijkervet FK, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer. 2003;88(7):1012-6.
  303. Wijers OB, Levendag PC, et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys. 2001;50(2):343-52.
  304. Henriksson R, Bergstrom P, et al. Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Acta Oncol. 1999;38(2):159-64.
  305. Carl UM, Feldmeier JJ, et al. Hyperbaric oxygen therapy for late sequelae in women receiving radiation after breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2001;49(4):1029-31.
  306. Kaul R, Mishra BK, et al. The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers--a clinical phase-III randomized trial. Indian J Cancer. 1999;36(2-4):141-8.
  307. Dale PS, Tamhankar CP, et al. Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects. Cancer Chemother Pharmacol. 2001;47 Suppl:29-34.
  308. Lehmann PV. Immunomodulation by proteolytic enzymes. Nephrol Dial Transplant. 1996;11(6):952-5.
  309. Gujral MS, Patnaik PM, et al. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol. 2001;47 Suppl:23-8.
  310. Maltoni M, Pirovano M, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer. 1995;75(10):2613-22.
  311. Brown CG, Wingard J. Clinical consequences of oral mucositis. Semin Oncol Nurs. 2004a;20(1):16-21.
  312. van der Reijden WA, van der Kwaak H, et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjogren's syndrome. Arthritis Rheum. 1996;39(1):57-63.
  313. Krishnasamy M. Oral problems in advanced cancer. Eur J Cancer Care (Engl). 1995;4(4):173-7.
  314. van Bokhorst-de van der S, van Leeuwen PA, et al. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer. 1999;86(3):519-27.
  315. Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol. 2000;34(3):137-68.
  316. Davis MP, Dreicer R, et al. Appetite and cancer-associated anorexia: a review. J Clin Oncol. 2004;22(8):1510-7.
  317. Wigmore SJ, Barber MD, et al. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36(2):177-84.
  318. Lissoni P, Paolorossi F, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer. 1996b;32A(8):1340-3.
  319. Mantovani G, Madeddu C, et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1651-9.
  320. Bruera E, Strasser F, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003;21(1):129-34.
  321. Tsujino K, Hirota S, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2003;55(1):110-5.
  322. Song L, Wang D, et al. The protective action of taurine and L-arginine in radiation pulmonary fibrosis. J Environ Pathol Toxicol Oncol. 1998;17(2):151-7.
  323. Rube CE, Wilfert F, et al. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol. 2002;64(2):177-87.
  324. Kwon HC, Kim SK, et al. Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother Oncol. 2000;56(2):175-9.
  325. Chytil F. The lungs and vitamin A. Am J Physiol. 1992;262(5 Pt 1):517-27.
  326. Redlich CA, Grauer JN, et al. Characterization of carotenoid, vitamin A, and alpha-tocopheral levels in human lung tissue and pulmonary macrophages. Am J Respir Crit Care Med. 1996;154(5):1436-43.
  327. Zitnik RJ, Kotloff RM, et al. Retinoic acid inhibition of IL-1-induced IL-6 production by human lung fibroblasts. J Immunol. 1994;152(3):1419-27.
  328. Redlich CA, Rockwell S. et al. Vitamin A inhibits radiation-induced pneumonitis in rats. J Nutr. 1998;128(10):1661-4.
  329. Anonymous. Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44(3):619-25.
  330. Goldsmith B. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron. Acta Oncol. 2004;43 Suppl 15:19-22.
  331. Henriksson R, Lomberg H, et al. The effect of ondansetron on radiation-induced emesis and diarrhoea. Acta Oncol. 1992;31(7):767-9.
  332. Zeltzer LK, Dolgin MJ, et al. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics. 1991;88(1):34-42.
  333. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med. 1982;307(24):1476-80.
  334. Dundee JW, Ghaly RG, et al. Effect of stimulation of the P6 antiemetic point on postoperative nausea and vomiting. Br J Anaesth. 1989a Nov;63(5):612-8.
  335. Dundee JW, Ghaly RG, et al. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. J R Soc Med. 1989b May;82(5):268-71.
  336. Mayer DJ. Acupuncture: an evidence-based review of the clinical literature. Annu Rev Med. 2000;51:49-63.
  337. Johnstone PA, Polston GR, et al. Integration of acupuncture into the oncology clinic. Palliat Med. 2002 May;16(3):235-9.
  338. Lu W. Acupuncture for side effects of chemoradiation therapy in cancer patients. Semin Oncol Nurs. 2005 Aug;21(3):190-5.
  339. Samuels N. [Acupuncture for nausea: how does it work?]. Harefuah. 2003 Apr;142(4):297-300, 316.
  340. Fossa SD. Long-term sequelae after cancer therapy--survivorship after treatment for testicular cancer. Acta Oncol. 2004;43(2):134-41.
  341. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate. 2001;46(2):98-107.
  342. Curtis RE, Boice JD, Jr, et al. Summary: multiple primary cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:219-42.
  343. Somerville HM. Second malignant neoplasms following treatment for primary cancer. Aust Fam Physician. 2003;32(1-2):25-31.
  344. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002;2(2):124-32.
  345. Ng AK, Bernardo MV, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100(6):1989-96.
  346. Travis LB. Therapy-associated solid tumors. Acta Oncol. 2002;41(4):323-33.
  347. Incrocci L, Slob AK, et al. Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys. 2002;52(3):681-93.
  348. Incrocci L, Hop WC, et al. Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. Urology. 2003;62(1):116-20.
  349. Hartman P, Diddle AW. Vaginal stenosis following irradiation therapy for carcinoma of the cervix uteri. Cancer. 1972;30(2):426-9.
  350. Lancaster L. Preventing vaginal stenosis after brachytherapy for gynaecological cancer: an overview of Australian practices. Eur J Oncol Nurs. 2004;8(1):30-9.
  351. Abitbol MM, Davenport JH. The irradiated vagina. Obstet Gynecol. 1974;44(2):249-56.
  352. Bergmark K, Avall-Lundqvist E, et al. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med. 1999;340(18):1383-9.
  353. Fraunholz IB, Schopohl B, et al. Management of radiation injuries of vulva and vagina. Strahlenther Onkol. 1998;174 Suppl 3:90-2.
  354. Grigsby PW, Russell A, et al. Late injury of cancer therapy on the female reproductive tract. Int J Radiat Oncol Biol Phys. 1995;31(5):1281-99.
  355. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol. 2005;16 Suppl 2:ii258-ii264.
  356. Fortin A, Couture C, et al. Does histologic grade have a role in the management of head and neck cancers? J Clin Oncol. 2001 Nov 1;19(21):4107-16.
  357. Hunter SE, Scher RL. Clinical implications of radionecrosis to the head and neck surgeon. Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):103-6.
  358. Eisbruch A, Dawson L. Re-irradiation of head and neck tumors. Benefits and toxicities. Hematol Oncol Clin North Am. 1999 Aug;13(4):825-36.
  359. Abayomi OK. Neck irradiation, carotid injury and its consequences. Oral Oncol. 2004 Oct;40(9):872-8.
  360. Dorresteijn LD, Kappelle AC, et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol. 2002 Jan 1;20(1):282-8.
  361. Lassen UN, Osterlind K, et al. Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer. 1999 Feb;79(3-4):515-9.
  362. Brown JK, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2003;53(5):268-91.
  363. Boyd NF, Greenberg C, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst. 1997 Apr 2;89(7):488-96.
  364. Rao CV, Reddy BS. Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandins production during colon carcinogenesis in male F344 rats. Carcinogenesis. 1993;14(7):1327-33.
  365. Prasad KN, Kumar A, et al. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr. 1999;18(1):13-25.
  366. McGough C, Baldwin C, et al. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. Br J Cancer. 2004;90(12):2278-87.
  367. Bye A, Kaasa S, et al. The influence of low fat, low lactose diet on diarrhoea during pelvic radiotherapy. Clin Nutr. 1992;11:147-53.
  368. Stryker JA, Bartholomew M. Failure of lactose-restricted diets to prevent radiation-induced diarrhea in patients undergoing whole pelvis irradiation. Int J Radiat Oncol Biol Phys. 1986;12(5):789-92.
  369. Delia P, Sansotta G, et al. Prophylaxis of diarrhoea in patients submitted to radiotherapeutic treatment on pelvic district: personal experience. Dig Liver Dis. 2002;34 Suppl 2:84-6.
  370. Salminen E, Elomaa I, et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol. 1988;39(4):435-7.
  371. Bounous G. The use of elemental diets during cancer therapy (review). Anticancer Res. 1983;3(5):299-304.
  372. Brown MS, Buchanan RB, et al. Clinical observations on the effects of elemental diet supplementation during irradiation. Clin Radiol. 1980;31(1):19-20.
  373. Craighead PS, Young S. Phase II study assessing the feasibility of using elemental supplements to reduce acute enteritis in patients receiving radical pelvic radiotherapy. Am J Clin Oncol. 1998;21(6):573-8.
  374. McArdle AH, Reid EC, et al. Prophylaxis against radiation injury. The use of elemental diet prior to and during radiotherapy for invasive bladder cancer and in early postoperative feeding following radical cystectomy and ileal conduit. Arch Surg. 1986;121(8):879-85.
  375. Kennedy M, Bruninga K, et al. Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. Am J Gastroenterol. 2001;96(4):1080-4.
  376. El Younis C, Abulafia O. The therapeutic role of antioxidant vitamins: C and E in radiation-induced rectal injury. Gastroenterology. 2003;124(4, Suppl 1):S1771.
  377. Irvine D, Vincent L, et al. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs. 1994;17(5):367-78.
  378. Geinitz H, Zimmermann FB, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):691-8.
  379. Janda M, Gerstner N, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer. 2000;89(6):1322-8.
  380. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(6 Suppl):1684-8.
  381. Jacobsen PB, Thors CL. Fatigue in the radiation therapy patient: current management and investigations. Semin Radiat Oncol. 2003;13(3):372-80.
  382. Courneya KS. Exercise in cancer survivors: an overview of research. Med Sci Sports Exerc. 2003;35(11):1846-52.
  383. Windsor PM, Nicol KF, et al. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer. 2004;101(3):550-7.
  384. Mock V, Dow KH, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum. 1997;24(6):991-1000.